Search Results - "Pisarczyk, K."

Filling the gap in CNS drug development: evaluation of the role of drug repurposing by Caban, A., Pisarczyk, K., Kopacz, K., Kapuśniak, A., Toumi, M., Rémuzat, C., Kornfeld, A.

“…Background and objective: Background and objective: Drug repurposing has been considered a cost-effective and reduced-risk strategy for developing new drugs…”
Get full text

CORRELATIONS BETWEEN BIOMARKERS AND CLINICAL OUTCOMES AMONG SELECT PRIMARY IMMUNE REGULATORY DISORDERS (PIRDS) by Harrington, A., Pisarczyk, K., Lopes, J. Matias, Rider, N., Beckerman, R.

“…PIRDs, a subset of inborn errors of immunity, are associated with genetic variants and characterized by autoimmunity, autoinflammation, and…”
Get full text

RO2 Analysis of Reimbursement Outcomes for Orphan Drugs with EMA Exceptional Circumstances Designation in France, Germany, and the UK by Lach, K., Pisarczyk, K., Beckerman, R., Meletiche, D.

Get full text

PNS20 RECENT ADVANCES IN THE EUROPEAN CROSS-BORDER COLLABORATIONS IN JOINT DRUG PROCUREMENT LANDSCAPE by Pisarczyk, K., Rémuzat, C., Skowron, R., Toumi, M.

Get full text

PCP15 - WHY EUROPEAN CROSS-BORDER INITIATIVES ON DRUG PROCUREMENT MAY FAIL? by Pisarczyk, K., Hajjeji, B., Rémuzat, C., Espín, J., Toumi, M.

Get full text

PCP18 - EUROPEAN CROSS-BORDER INITIATIVES ON DRUG PROCUREMENT: A MARKER OF HTA FAILURE? by Pisarczyk, K., Rémuzat, C., Hajjeji, B., Toumi, M.

Get full text

PCP8 - BENELUXA INITIATIVE: WHY THE FIRST ATTEMPT OF JOINT ASSESSMENT FAILED? by Pisarczyk, K., Rémuzat, C., Hajjeji, B., Toumi, M.

Get full text

HT3 - DESCRIPTION AND COMPARISON OF EUROPEAN CROSS-BORDER INITIATIVES ON DRUG PROCUREMENT by Pisarczyk, K., Hajjeji, B., Rémuzat, C., Espín, J., Toumi, M.

Get full text

PRM230 - Trends in Pragmatic Clinical Trials by Kloc, K, Pisarczyk, K, Lach, S, Rémuzat, C, Toumi, M

Get full text

Trends in Pragmatic Clinical Trials by Kloc, K, Pisarczyk, K, Lach, S, Rémuzat, C, Toumi, M

“…OBJECTIVES: Pragmatic clinical trials (PCTs) are gaining interest among decision-makers as transferability and generalisability of clinical trial results to…”
Get full text

PHP368 - Beyond Risk-Based Vaccination Policies - A Life-Course Approach to Vaccination by Lach, K, Jaroslawski, S, Pisarczyk, K, Toumi, M

Get full text

Beyond Risk-Based Vaccination Policies - A Life-Course Approach to Vaccination by Lach, K, Jaroslawski, S, Pisarczyk, K, Toumi, M

Get full text

Patient-Reported Outcomes in Randomized Controlled Trials for Overactive Bladder : A Systematic Literature Review by Germain, N, Aballéa, S, Smela-Lipinska, B, Pisarczyk, K, Keskes, M, Toumi, M

Get full text

PUK13 - Patient-Reported Outcomes in Randomized Controlled Trials for Overactive Bladder : A Systematic Literature Review by Germain, N, Aballéa, S, Smela-Lipinska, B, Pisarczyk, K, Keskes, M, Toumi, M

Get full text

PRM116 - GENERAL PERCEPTIONS OF INNOVATIVE METHODS FOR SURVIVAL EXTRAPOLATION IN ONCOLOGY AMONG HTA IN EUROPE, CANADA AND AUSTRALIA by Pochopien, M, Contente, M, Toumi, M, Sherman, S, Aballea, S, Lach, S, Pisarczyk, K, Johannesen, KM, Malcolm, B

Get full text

PRM146 - CURRENT AND FUTURE TRENDS IN METHODOLOGIES OF SURVIVAL CURVE EXTRAPOLATION IN ONCOLOGY ACCEPTED BY HTA AUTHORITIES by Pochopien, M, Malcolm, B, Toumi, M, Sherman, S, Aballea, S, Pisarczyk, K, Lach, S, Johannesen, KM, Contente, M

Get full text

Improved Al/InP Schottky barriers by coimplantation of Be/P by TYAGI, R, CHOW, T. P, BORREGO, J. M, PISARCZYK, K. A

“…Improved Al/InP Schottky barriers are formed on n-InP by using coimplantation of Be/P. The doped surface layer (Be) helps in retarding the surface fields,…”
Get full text

Committee report: research needs for the treatment of iron and manganese. Trace inorganic substances committee by ROBINSON, B. R, DART, F. J, PISARCZYK, K, SINGER, P. C, SUNG, W

Get full text

Committee Report: Research Needs for the Treatment of Iron and Manganese by Robinson, R.B., Dart, F.J., Pisarczyk, K., Singer, P.C., Sung, W.

“…Iron and manganese problems affect far more water systems than almost any other water quality concern. The committee that prepared this report believes there…”
Get full text

Improved Al/InP Schottky barriers by coimplantation of Be/P by Tyagi, R., Chow, T.P., Borrego, J.M., Pisarczyk, K.A.

“…The development of conventional InP MESFET technology is strongly hampered by the low barrier height (0.3-0.4eV) obtained in InP, due to surface Fermi level…”
Get full text